{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT02928978",
            "orgStudyIdInfo": {
                "id": "H-38855"
            },
            "organization": {
                "fullName": "Baylor Breast Care Center",
                "class": "OTHER"
            },
            "briefTitle": "Ruxolitinib for Premalignant Breast Disease",
            "officialTitle": "TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions",
            "acronym": "TBCRC042",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "ruxolitinib-for-premalignant-breast-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2022-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2018-05-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2016-10-07",
            "studyFirstSubmitQcDate": "2016-10-07",
            "studyFirstPostDateStruct": {
                "date": "2016-10-10",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2022-05-09",
            "lastUpdatePostDateStruct": {
                "date": "2022-05-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Julie Nangia",
                "investigatorTitle": "Assistant Professor",
                "investigatorAffiliation": "Baylor Breast Care Center"
            },
            "leadSponsor": {
                "name": "Julie Nangia",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Incyte Corporation",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Translational Breast Cancer Research Consortium",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitinib or placebo, participants will undergo surgery to remove the premalignant breast tissue."
        },
        "conditionsModule": {
            "conditions": [
                "Ductal Carcinoma In Situ",
                "Atypical Lobular Hyperplasia",
                "Atypical Ductal Hyperplasia",
                "Lobular Carcinoma In Situ"
            ],
            "keywords": [
                "Premalignant Breast Disease",
                "ALH",
                "ADH",
                "DCIS",
                "LCIS",
                "Breast Cancer Prevention",
                "Ruxolitinib"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Ruxolitinib",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive ruxolitinib 20 mg by mouth twice daily for 15 days (+/- 5 days). Ruxolitinib will be supplied as four, 5 mg tablets.",
                    "interventionNames": [
                        "Drug: Ruxolitinib"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will receive a placebo (sugar pill) that is designed to mimic ruxolitinib. The placebo will be supplied as four, 5 mg tablets. Participants assigned to this arm will take four, 5 mg tablets by mouth twice daily for 15 days (+/- 5 days).",
                    "interventionNames": [
                        "Drug: Placebo (for Ruxolitinib)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Ruxolitinib",
                    "description": "tablet (taken by mouth)",
                    "armGroupLabels": [
                        "Ruxolitinib"
                    ],
                    "otherNames": [
                        "Jakafi",
                        "INCB018424"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo (for Ruxolitinib)",
                    "description": "tablet (taken by mouth)",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in Apoptosis",
                    "description": "The number of premalignant breast cells in apoptosis at the time of diagnosis will be compared to the number of cells in apoptosis following treatment with 15 (+/- 5) days of ruxolitinib or placebo.",
                    "timeFrame": "15 days (+/- 5 days)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "pSTAT5",
                    "description": "To determine the difference in change in pSTAT5 levels between diagnosis and surgery as a function of ruxolitinib treatment versus placebo",
                    "timeFrame": "15 days (+/- 5 days)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Have a breast biopsy showing ADH (atypical ductal hyperplasia), ALH (atypical lobular hyperplasia), LCIS (lobular carcinoma in situ), or DCIS (ductal carcinoma in situ) requiring surgical excision. Microinvasive disease is allowed.\n\n  * NOTE: Tissue from the diagnostic biopsy must be accessible/available for research correlates (i.e., a tissue block or \\~10 unstained slides). Due to the nature of the study, fewer slides may be accepted with prior permission from the Protocol Chair if there is insufficient tissue.\n* Women and men age 18 and older.\n* Adequate hematologic and organ function, defined as follows:\n\n  * Absolute neutrophil count \u2265 1500/mm3\n  * Hemoglobin \u2265 9.0 g/dL\n  * Platelet levels \\>200 x 109/L\n  * Total bilirubin \u2264 1.5 x institutional upper limit of normal (ULN)\n  * AST/ALT \u2264 2.5 x institutional ULN\n  * Alkaline phosphatase \u2264 5 x institutional ULN\n  * Creatinine clearance \\> 50 mL/min as calculated by the Cockcroft-Gault method\n* Willing to not use concomitant strong CYP3A4 inhibitors as this could interfere with the metabolism of ruxolitinib (i.e azole antifungals, clarithromycin, conivaptan, grapefruit juice, mibefradil, nefazodone, protease inhibitors, telithromycin).\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.\n* If the patient undergoes germline genetic testing, the results must be received prior to randomization, as the results may affect the surgical approach and, in turn, the date of surgical excision.\n* Patient understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Treatment with selective estrogen receptor modulators (SERMs) or aromatase inhibitors for breast cancer prevention within 1 year prior to starting study treatment.\n* Treatment with any other investigational agents within 30 days of starting study treatment.\n* Current diagnosis of invasive breast cancer (current microinvasive disease is allowed), or previous history of invasive breast cancer diagnosed within the last 5 years.\n\nNOTE: If previous history of ER+ invasive breast cancer diagnosed \\> 5 years ago, patient must be off endocrine therapy for at least 1 year prior to starting study treatment.\n\n* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, end stage renal disease (ESRD), or psychiatric illness/social situations that would limit compliance with study requirements.\n* Women who are pregnant or nursing.\n* HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ruxolitinib.\n* Prior or current treatment with a JAK inhibitor, for any indication.\n* Known active Hepatitis B or C.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Kristen Otte",
                    "role": "CONTACT",
                    "phone": "713-798-8874",
                    "email": "clinical-research@breastcenter.tmc.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Julie Nangia, M.D.",
                    "affiliation": "Baylor College of Medicine",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Alabama at Birmingham",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35294",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Shelley Hill",
                            "role": "CONTACT",
                            "phone": "205-934-4173",
                            "email": "shill26@uab.edu"
                        },
                        {
                            "name": "Catherine Parker, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "Indiana University Melvin and Bren Simon Cancer Center",
                    "status": "RECRUITING",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Versie Barnes",
                            "role": "CONTACT",
                            "phone": "317-278-3127",
                            "email": "barnesv@iu.edu"
                        },
                        {
                            "name": "Carla Fisher, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                },
                {
                    "facility": "Montefiore Medical Center",
                    "status": "RECRUITING",
                    "city": "Bronx",
                    "state": "New York",
                    "zip": "10461",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anton Lulaj",
                            "role": "CONTACT",
                            "phone": "718-405-8539",
                            "email": "alulaj@montefiore.org"
                        },
                        {
                            "name": "Sheldon Feldman, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.84985,
                        "lon": -73.86641
                    }
                },
                {
                    "facility": "University of North Carolina at Chapel Hill",
                    "status": "RECRUITING",
                    "city": "Chapel Hill",
                    "state": "North Carolina",
                    "zip": "27599",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Crissey Tait",
                            "role": "CONTACT",
                            "phone": "984-974-8675",
                            "email": "crissey_tait@med.unc.edu"
                        },
                        {
                            "name": "Kristalyn Gallagher, DO",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.9132,
                        "lon": -79.05584
                    }
                },
                {
                    "facility": "Vanderbilt-Ingram Cancer Center",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37232",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials Information Program",
                            "role": "CONTACT",
                            "phone": "800-811-8480"
                        },
                        {
                            "name": "Ingrid Meszoely, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Baylor College of Medicine",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Claudette Foreman",
                            "role": "CONTACT",
                            "phone": "713-798-7315",
                            "email": "cforema@bcm.edu"
                        },
                        {
                            "name": "Julie Nangia, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Mothaffar Rimawi, M.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Bora Lim, M.D.",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "C. Kent Osborne, M.D.",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "University of Texas MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Diane Weber, RN",
                            "role": "CONTACT",
                            "phone": "346-212-1287",
                            "email": "dweber@mdanderson.org"
                        },
                        {
                            "name": "Parijatham Thomas, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000002278",
                    "term": "Carcinoma in Situ"
                },
                {
                    "id": "D000044584",
                    "term": "Carcinoma, Ductal"
                },
                {
                    "id": "D000002285",
                    "term": "Carcinoma, Intraductal, Noninfiltrating"
                },
                {
                    "id": "D000011230",
                    "term": "Precancerous Conditions"
                },
                {
                    "id": "D000018275",
                    "term": "Carcinoma, Lobular"
                },
                {
                    "id": "D000071960",
                    "term": "Breast Carcinoma In Situ"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000006965",
                    "term": "Hyperplasia"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000018299",
                    "term": "Neoplasms, Ductal, Lobular, and Medullary"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M10016",
                    "name": "Hyperplasia",
                    "asFound": "Hyperplasia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14111",
                    "name": "Precancerous Conditions",
                    "asFound": "Premalignant",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "asFound": "Breast Diseases",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5535",
                    "name": "Carcinoma in Situ",
                    "asFound": "Carcinoma in Situ",
                    "relevance": "HIGH"
                },
                {
                    "id": "M25356",
                    "name": "Carcinoma, Ductal",
                    "asFound": "Ductal Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20420",
                    "name": "Carcinoma, Lobular",
                    "asFound": "Lobular Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5542",
                    "name": "Carcinoma, Intraductal, Noninfiltrating",
                    "asFound": "Atypical Ductal Hyperplasia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M895",
                    "name": "Breast Carcinoma In Situ",
                    "asFound": "Lobular Carcinoma in Situ",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        }
    },
    "hasResults": false
}